U.S., May 15 -- ClinicalTrials.gov registry received information related to the study (NCT07587034) titled 'HAIC-TACE Plus Apatinib and Camrelizumab for Liver Cancer' on May 08.
Brief Summary: To provide evidence-based medical evidence for the optimized combination strategy of local and systemic therapies.
Study Start Date: June, 2026
Study Type: INTERVENTIONAL
Condition:
Liver Cancer
Intervention:
PROCEDURE: HTAC
Patients will first undergo hepatic arterial infusion chemotherapy (HAIC) treatment. Subsequently, transarterial chemoembolization (TACE) will be administered sequentially following the completion of HAIC. This regimen will be combined with apatinib (a vascular endothelial growth factor receptor 2 [VEGFR-2] inhibitor) and ...